Shopping Cart
Remove All
Your shopping cart is currently empty
Amivantamab
🥰Excellent
Catalog No. T9901A-1551Cas No. 2171511-58-1
Alias JNJ-61186372, JNJ61186372
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.
Amivantamab
Amivantamab
🥰Excellent
Catalog No. T9901A-1551Alias JNJ-61186372, JNJ61186372Cas No. 2171511-58-1
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.
Product information is being updated, if you want to purchase, please click the bulk custom button.
Add to Quotation
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer. |
| In vitro | In Ba/F3 cells treated with Amivantamab ranging from 0.05 to 1 mg/mL, a significant and dose dependent decrease in Ba/F3 cell viability (P < 0.0001) was observed in all five EGFR Exon20ins mutations. [1] |
| In vivo | Mice were treated with amivantamab, IgG1 control, or vehicle at 30 mg/kg twice per week intraperitoneally. Amivantamab-treated mice showed reduced tumor volumes in the Ba/F3 cells bearing NOD. [1] |
| Synonyms | JNJ-61186372, JNJ61186372 |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | c-Met/EGFR |
| Molecular Weight | 145.9 kDa |
| Cas No. | 2171511-58-1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Amivantamab | purchase Amivantamab | Amivantamab cost | order Amivantamab | Amivantamab in vivo | Amivantamab in vitro | Amivantamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.